Tocilizumab versus adalimumab for rheumatoid arthritis - Authors' reply
Contributeurs/tricesGabay, Cem; Kavanaugh, Arthur
Publié dansLancet, vol. 382, no. 9890, 395
Date de publication2013
Mots-clés
- Antibodies, Monoclonal, Humanized/therapeutic use
- Antirheumatic Agents/therapeutic use
- Arthritis, Rheumatoid/therapy
- Female
- Humans
- Male
Structure d'affiliation
Groupe de recherche
Citation (format ISO)
GABAY, Cem, KAVANAUGH, Arthur. Tocilizumab versus adalimumab for rheumatoid arthritis - Authors” reply. In: Lancet, 2013, vol. 382, n° 9890, p. 395. doi: 10.1016/S0140-6736(13)61670-0
Fichiers principaux (1)
Article (Published version)
Identifiants
- PID : unige:73679
- DOI : 10.1016/S0140-6736(13)61670-0
- PMID : 23911377
ISSN du journal0140-6736
